{"doi":"10.1002/mdc3.13893","title":"Meta‐analysis of Association between Newer Glucose‐Lowering Drugs and Risk of Parkinson's Disease","abstract":"Background: The association between newer classes of glucose-lowering drugs (GLDs) and the risk of Parkinson's disease (PD) remains unclear. Objective: The aim was to examine the effect of newer GLDs on the risk of PD through a meta-analysis of randomized outcome trials. Methods: The methods included randomized placebo-controlled outcome trials that reported PD events associated with three newer classes of GLDs (ie, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, and sodium-glucose co-transporter-2 inhibitors) in participants with or without type 2 diabetes. The pooled odds ratio (OR) and 95% confidence interval (CI) were estimated using Peto's method. Results: The study included 24 trials involving 33 PD cases among 185,305 participants during a median follow-up of 2.2 years. Newer GLDs were significantly associated with a lower PD risk (OR: 0.50; 95% CI: 0.25-0.98) than placebo. Conclusion: Newer GLDs may possibly be associated with a decreased risk of PD; however, larger datasets are required to confirm or refute this notion.","journal":"Movement Disorders Clinical Practice","year":2023,"id":345031,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":13,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9351,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":50832,"name":"Ying Lü","orcid":"0000-0002-7698-8962","position":1,"is_corresponding":false},{"id":271889,"name":"Michael S. Okun","orcid":"0000-0002-6247-9358","position":2,"is_corresponding":false},{"id":404842,"name":"William T. Donahoo","orcid":"0000-0002-2126-860X","position":3,"is_corresponding":false},{"id":345831,"name":"Adolfo Ramirez–Zamora","orcid":"0000-0001-9253-3899","position":4,"is_corresponding":false},{"id":240709,"name":"Fei Wang","orcid":"0000-0001-9459-9461","position":5,"is_corresponding":false},{"id":1083987,"name":"Yu Huang","orcid":"0000-0002-0068-3716","position":6,"is_corresponding":false},{"id":1083988,"name":"Wei‐Han Chen","orcid":"0000-0001-8545-6127","position":7,"is_corresponding":false},{"id":601966,"name":"Beth A Virnig","orcid":"0000-0002-8153-7488","position":8,"is_corresponding":false},{"id":23318,"name":"Jiang Bian","orcid":"0000-0002-2238-5429","position":9,"is_corresponding":false},{"id":415391,"name":"Jingchuan Guo","orcid":"0000-0001-9799-2592","position":10,"is_corresponding":false},{"id":545934,"name":"Huilin Tang","orcid":"0000-0002-5814-6657","position":0,"is_corresponding":true}],"reference_count":42,"raw_metadata":null,"created_at":"2026-07-19T01:11:35.133818Z","pmid":"37982117","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}